Back to top

New Strong Buy Stocks for October 17th

Read MoreHide Full Article

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Atlas Air Worldwide Holdings, Inc. (AAWW - Free Report) : This company that provides outsourced aircraft and aviation operating services has seen the Zacks Consensus Estimate for its current year earnings increasing 0.7% over the last 60 days.

Atlas Air Worldwide Holdings Price and Consensus

 

Atlas Air Worldwide Holdings Price and Consensus

Atlas Air Worldwide Holdings price-consensus-chart | Atlas Air Worldwide Holdings Quote

Denbury Resources Inc. (DNR - Free Report) : This independent oil and natural gas company has seen the Zacks Consensus Estimate for its current year earnings increasing 4.3% over the last 60 days.Eni S.p.A. (E - Free Report) : This company that engages in the oil and gas, electricity generation and sale, and petrochemicals businesses has seen the Zacks Consensus Estimate for its current year earnings increasing 11.9% over the last 60 days.

Eni SpA Price and Consensus

 

Eni SpA Price and Consensus

Eni SpA price-consensus-chart | Eni SpA Quote

Matson, Inc. (MATX - Free Report) : This company that provides ocean transportation and logistics services has seen the Zacks Consensus Estimate for its current year earnings increasing 0.9% over the last 60 days.

Matson, Inc. Price and Consensus

 

Matson, Inc. Price and Consensus

Matson, Inc. price-consensus-chart | Matson, Inc. Quote

Ternium S.A. (TX - Free Report) : This company that manufactures and processes various steel products has seen the Zacks Consensus Estimate for its current year earnings increasing 6% over the last 60 days.

Ternium S.A. Price and Consensus

 

Ternium S.A. Price and Consensus

Ternium S.A. price-consensus-chart | Ternium S.A. Quote

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>



More from Zacks Zacks #1 Rank Additions

You May Like